journal article·2021-06

Polyvinylpyrrolidone functionalization induces deformable structure of graphene oxide nanosheets for lung-targeting delivery

Hongyang Yu, Bing Wang, Shuang Zhou, Meilin Zhu, Wei Chen, Hanqing Chen, Xue Li, Shanshan Liang, Meng Wang, Lingna Zheng, Lina Zhao, Zhifang Chai, Weiyue Feng

Nano Today· Volume 38
Publisher page

Abstract

Abstract Nanomaterials (NMs) as lung-targeted drug delivery vehicles have attracted great attentions. Recent studies indicated that elastic or deformable property of NMs could play a vital role in biomedical applications. Herein, polyvinylpyrrolidone (PVP) functionalized graphene oxide (GO-PVP) via a facile one-pot method and PEGylated GO (GO-PEG) nanosheets (NSs) were synthesized at room temperature. By using rare earth elemental labeling method, we quantitatively revealed that GO-PVP NSs were targeting retention in the lung that after 4 h intravenous injection, the lung/liver and lung/spleen ratios in GO-PVP treated mice were about 230-fold and 30-fold higher of those in GO-PEG treated mice, respectively, especially a considerable amount was retained in the lower respiratory tract including pulmonary interstitium and alveolar region as fibril-like shapes. The florescence imaging and in situ confocal Raman microscopy combining with laser-ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) elemental imaging analysis further confirmed that a more amount of GO-PVP than GO-PEG retention in the pulmonary interstitium. Utilizing atomic force microscopy PeakForce quantitative nanomechanical mapping technique, the nanomechanical property investigation shows that GO-PVP NSs are softer, more adhesive and deformable than GO-PEG NSs. Further, the molecular dynamics simulations illustrate that GO-PVP has deformable structure due to the hydrogen-bond interaction at basal plane between PVP and GO that cause GO-PVP surface roughness and to possess low solvent accessible surface area (SASA), comparatively, the GO-PEG owns relatively firm structure and higher SASA. This study indicates that the well dispersion property and deformable structure of GO-PVP in the lung contribute to its filtration of the endothelial/epithelial barrier and retention in the interstitium and alveolar region. Importantly, the study inspires us to design elastic or deformable NMs in response to the lung disease especially those have occurred in the lower respiratory tract.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · Diamond and Carbon-based Materials Research · Graphene research and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (56)

Show source-provided references
1. Chronic respiratory diseases: a global view10.1016/S2213-2600(20)30157-0 ↗
2. Getting carried away10.1038/s41579-020-0325-z ↗
3. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China10.1016/S0140-6736(20)30183-5 ↗
4. Physicochemical properties of nanoparticles regulate translocation across pulmonary surfactant monolayer and formation of lipoprotein corona10.1021/nn4054683 ↗
5. Screening for natural and derived bio-active compounds in preclinical and clinical studies: one of the frontlines of fighting the coronaviruses pandemic
6. Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases10.1016/j.jconrel.2020.07.002 ↗
7. Metal–organic framework microsphere formulation for pulmonary administration10.1021/acsami.0c07356 ↗
8. Monosized polymeric microspheres designed for passive lung targeting: biodistribution and pharmacokinetics after intravenous administration10.1021/acsnano.9b09773 ↗
9. Nanoparticle-mediated pulmonary drug delivery: a review10.3390/ijms15045852 ↗
10. Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity10.1126/science.aau0810 ↗
11. Critical determinants of uptake and translocation of nanoparticles by the human pulmonary alveolar epithelium10.1021/nn505399e ↗
12. Rapid translocation of nanoparticles from the lung airspaces to the body10.1038/nbt.1696 ↗
13. Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system10.1016/j.apsb.2018.08.006 ↗
14. Graphene nanoribbons: a promising nanomaterial for biomedical applications10.1016/j.jconrel.2020.06.034 ↗
15. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles10.1038/s41392-019-0068-3 ↗
16. Enhanced antibacterial activity through the controlled alignment of graphene oxide nanosheets10.1073/pnas.1710996114 ↗
17. Splenic capture and in vivo intracellular biodegradation of biological-grade graphene oxide sheets10.1021/acsnano.0c03438 ↗
18. Effect of size and dose on the biodistribution of graphene oxide in mice10.2217/nnm.12.60 ↗
19. In vivo pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice10.1021/nn1024303 ↗
20. Plasticity and ductility in graphene oxide through a mechanochemically induced damage tolerance mechanism10.1038/ncomms9029 ↗
21. Nanoparticle elasticity directs tumor uptake10.1038/s41467-017-02588-9 ↗
22. Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting10.1021/acsnano.5b00147 ↗
23. Graphene thin films by noncovalent-interaction-driven assembly of graphene monolayers for flexible supercapacitors10.1016/j.chempr.2018.01.008 ↗
24. Mechanical properties of monolayer graphene oxide10.1021/nn101781v ↗
25. The effects of extensive glomerular filtration of thin graphene oxide sheets on kidney physiology10.1021/acsnano.6b03358 ↗
26. In vivo pharmacokinetics, transfer and clearance study of graphene oxide by La/Ce dual elemental labelling method10.1016/j.impact.2020.100213 ↗
27. Indocyanine green loaded reduced graphene oxide for in vivo photoacoustic/fluorescence dual-modality tumor imaging
28. Recent development of PeakForce tapping mode atomic force microscopy and its applications on nanoscience10.1515/ntrev-2018-0086 ↗
29. Force measurements with the atomic force microscope: technique, interpretation and applications10.1016/j.surfrep.2005.08.003 ↗
30. Superflexibility of graphene oxide10.1073/pnas.1605121113 ↗
31. Molecular deformation mechanism of polycarbonate during nano-indentation: molecular dynamics simulation and experimentation10.1016/j.polymer.2019.04.029 ↗
32. Impact of particle elasticity on particle-based drug delivery systems10.1016/j.addr.2016.01.007 ↗
33. Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers10.1038/s41467-018-05061-3 ↗
34. Hydrodynamic red blood cells deformation by quantitative phase microscopy and zernike polynomials10.3389/fphy.2019.00111 ↗
35. How leukocytes cross the vascular endothelium10.1038/nri3908 ↗
36. Role of deformable cancer cells on wall shear stress-associated-VEGF secretion by endothelium in microvasculature10.1371/journal.pone.0211418 ↗
37. Hydrophobic interactions and hydrogen bonds in β-sheet formation10.1063/1.4821596 ↗
38. The art of two-dimensional soft nanomaterials10.1007/s11426-019-9477-y ↗
39. Multi-hierarchical profiling the structure-activity relationships of engineered nanomaterials at nano-bio interfaces10.1038/s41467-018-06869-9 ↗
40. Vacancies on 2D transition metal dichalcogenides elicit ferroptotic cell death
41. Graphene oxide liquid crystals: a frontier 2D soft material for graphene-based functional materials10.1039/C8CS00299A ↗
42. Size‐dependent pulmonary impact of thin graphene oxide sheets in mice: toward safe‐by‐design10.1002/advs.201903200 ↗
43. The role of nanoparticle shape in translocation across the pulmonary surfactant layer revealed by molecular dynamics simulations10.1039/C8EN00521D ↗
44. Crucial role of lateral size for graphene oxide in activating macrophages and stimulating pro-inflammatory responses in cells and animals10.1021/acsnano.5b04751 ↗
45. Cytokine profiling of primary human macrophages exposed to endotoxin-free graphene oxide: size-independent NLRP3 inflammasome activation10.1002/adhm.201700815 ↗
46. Small, thin graphene oxide is anti-inflammatory activating nuclear factor erythroid 2-related factor 2 via metabolic reprogramming10.1021/acsnano.8b03642 ↗
47. Surface oxidation of graphene oxide determines membrane damage, lipid peroxidation, and cytotoxicity in macrophages in a pulmonary toxicity model10.1021/acsnano.7b07737 ↗
48. Minimizing oxidation and stable nanoscale dispersion improves the biocompatibility of graphene in the lung10.1021/nl202515a ↗
49. Pluronic F108 coating decreases the lung fibrosis potential of multiwall carbon nanotubes by reducing lysosomal injury10.1021/nl300895y ↗
50. Gold nanoparticles induced endothelial leakiness depends on particle size and endothelial cell origin10.1021/acsnano.7b01744 ↗
51. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE–cadherin10.1038/ncomms2655 ↗
52. Unique structural features that influence neutrophil emigration into the lung10.1152/physrev.00023.2002 ↗
53. Neutrophils, as “Trojan horses”, participate in the delivery of therapeutical PLGA nanoparticles into a tumor based on the chemotactic effect10.1080/10717544.2019.1701141 ↗
54. Accessing neuroinflammation sites: monocyte/neutrophil-mediated drug delivery for cerebral ischemia10.1126/sciadv.aau8301 ↗
55. Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-fig, mouse and rat: many are transcellular pores10.1111/j.1469-7793.1997.747bd.x ↗
56. Can graphene take part in the fight against COVID-1910.1016/j.nantod.2020.100883 ↗